Updated Management of Hypertension in Adults at Primary Care Level

Objectives

Improve prevention and comprehensive management of hypertension through primary health care, reducing cardiovascular and renal morbidity, mortality and target-organ complications.[1][2]The guideline combines population-wide prevention, individual cardiovascular-risk assessment, effective blood-pressure control and secondary prevention for people at elevated risk.[2][3]

• Prevent high blood pressure through integrated population-based risk management, healthy-lifestyle policies, public education, political commitment, professional advocacy, community leadership and mass-media involvement.[2]
• Identify cardiovascular risk, target-organ damage and associated conditions through medical history, physical examination, vital signs and routine investigations.[4][3]
• Stratify patients as having average, low, moderate, high or very high added cardiovascular risk to guide prognosis and management.[3][5]
• Control blood pressure to below 140/90 mmHg, or below 130/80 mmHg where co-morbidity is present, using a step-wise treatment pathway.[6][7]
• Prioritise lifestyle modification throughout hypertension management to lower blood pressure, improve medicine effectiveness and reduce cardiovascular risk.[5]
• Protect against established cardiovascular disease and target-organ damage through condition-specific antihypertensive medicine selection, including for angina, coronary artery disease, myocardial infarction, heart failure, left ventricular hypertrophy, stroke, diabetes, proteinuria and isolated systolic hypertension.[8]
• Empower people with non-communicable chronic diseases to participate actively in their care through education on hypertension, its consequences, risk-factor control, lifestyle change, treatment adherence, medicines, adverse effects, interactions and self-monitoring.[9]

The strategic focus is clinical and preventive hypertension care rather than a wider programme architecture.[1][2]The supplied material does not specify a separate programme-wide mission beyond these prevention, treatment and patient-empowerment objectives.[10][8][11][12]

Implementation

Deliver hypertension control principally through primary health care, supported by standardised assessment, patient education, risk-based treatment escalation, routine follow-up and referral to higher levels of care when necessary.[1][2][4]The National Department of Health's Directorate for Chronic Diseases, Disabilities and Geriatrics compiled the guideline, with acknowledged input from the Guideline Committee, the Southern African Hypertension Society, and national and provincial Department of Health colleagues.[13]

• Measure blood pressure accurately by using an appropriately sized cuff, assessing both arms at the first consultation, subsequently using the arm with the higher reading, and averaging two readings taken one minute apart.[9]
• Apply validated measurement procedures by ensuring appropriate posture, cuff size and rest period, recording blood pressure after at least five minutes of rest, and taking a standing reading where postural hypotension is a risk.[12]
• Diagnose hypertension only when blood pressure is at least 140/90 mmHg on three occasions within two months, and repeat readings that differ by 5 mmHg.[9]
• Assess weight, height, body mass index, waist circumference or waist-to-hip ratio, eye health, dietary adherence and activity levels, alongside urine, blood and other tests for diabetes, renal impairment, dyslipidaemia and cardiovascular risk.[4]
• Investigate suspected secondary or refractory hypertension and refer patients when secondary hypertension, resistant hypertension, target-organ damage or associated conditions cannot be managed in primary care.[4][3]
• Provide therapeutic education on weight reduction, smoking cessation, salt restriction, reduced alcohol and caffeine intake, prudent diet, regular moderate physical activity and avoiding liquorice.[5]
• Limit salt intake to less than 5 grams daily and alcohol intake to no more than two standard drinks daily for men and one for women, with alcohol cessation preferred.[5]
• Start uncomplicated stage 1 hypertension management with lifestyle modification, add low-dose hydrochlorothiazide when needed, and escalate with further medicine classes if blood pressure remains uncontrolled.[6][7]
• Avoid combining a thiazide diuretic with a beta-blocker for people with abdominal obesity and hypertension because of adverse metabolic effects and increased risk of new diabetes.[7][10]
• Increase antihypertensive doses stepwise to the maximum dosage where blood pressure is uncontrolled, reduce doses if postural hypotension occurs, and consider stepwise treatment reduction after one year of stable control.[8]
• Refer resistant hypertension to a doctor, specialist or hospital after checking adherence and lifestyle measures, including after failure of step 4 despite two months of compliance.[7][12]
• Hospitalise hypertensive emergencies immediately in intensive care for rapid blood-pressure reduction by experienced staff using modern monitoring facilities, while referring hypertensive urgency within one week and managing it with two oral agents and gradual diastolic reduction over 48 to 72 hours.[11][12]
• Inform patients of their individual blood-pressure reading and goal at every visit, involve families or carers, encourage return of medicine containers, and establish facility-based support groups addressing self-care, self-monitoring and behavioural change.[2][9]
• Monitor people receiving highly active antiretroviral therapy closely because prolonged treatment is associated with more systolic hypertension and antiretroviral medicines can alter calcium-channel-blocker and beta-blocker metabolism.[8][11]
• Review patients every six months after blood pressure has been controlled for one year, while using earlier reviews according to treatment step and urgency.[2][6][7]
• Service and calibrate blood-pressure devices and attachments at least every two years.[9]

The material identifies the Department of Health and Southern African Hypertension Society as stakeholders promoting lifestyle modification.[5]It does not specify a formal implementation governance structure, programme-level performance indicators, reporting or surveillance system, accountability arrangements, budgets or financing mechanisms.[10][8][11][12][9][14]

Monitoring & Evaluation

Monitoring centres on repeated, standardised clinical assessment of blood pressure, cardiovascular risk, treatment response, adherence and complications, rather than on a programme-wide evaluation system.[4][3][9]Follow-up intensity varies according to blood-pressure control, treatment step and clinical urgency.[6][7][11][12]

• Measure blood pressure accurately using an appropriately sized cuff; assess both arms at the first consultation, use the arm with the higher reading subsequently, and average two readings taken one minute apart.[9]Record blood pressure after at least five minutes of rest and, where postural hypertension is a concern, repeat measurement after one minute standing.[12]
• Record systolic and diastolic blood pressure, estimate systolic pressure by palpation before auscultation, identify systolic pressure at the first sound and diastolic pressure when the sound disappears.[9]Repeat readings that differ by 5 mmHg, and diagnose hypertension only when readings reach 140/90 mmHg on three occasions within two months.[9]
• Service and calibrate blood-pressure devices and attachments at least every two years.[9]
• Assess body weight, body mass index, waist circumference or waist-to-hip ratio, blood pressure, dietary compliance and activity levels at specified visits.[4]Measure height at the first visit, assess eye health at the first visit and annually where normal, and perform urine dipstick testing at the first visit and annually where normal, with earlier repeat testing for abnormal findings.[4]
• Perform micro-albuminuria testing at diagnosis for type 2 diabetes mellitus or five years after diagnosis for type 1 diabetes mellitus, then annually.[4]Repeat creatinine, potassium and relevant blood tests annually where results are normal.[4]
• Use medical history, physical examination, vital signs and routine investigations to assess cardiovascular risk and identify diabetes, renal impairment, dyslipidaemia, target-organ damage and associated clinical conditions.[4][3]Use the European Society of Hypertension and European Society of Cardiology cardiovascular disease risk assessment model and specified risk-stratification table to classify prognosis from average to very high added risk.[3][5]
• Assess blood-pressure control against targets below 140/90 mmHg, or below 130/80 mmHg where co-morbidity is present.[6][7]Review initial lifestyle management within six months, steps 2 and 3 within three months, step 4 within one to two months, and resistant hypertension as soon as possible.[6][7]
• Conduct medical assessment every six months once target blood pressure has been stable for one year.[2][8]Consider stepwise treatment reduction after blood pressure has remained controlled for one year, while monitoring dizziness and excessively low standing systolic pressure for postural hypotension.[8]
• Monitor blood pressure and review doses frequently for people receiving highly active antiretroviral therapy, as treatment is associated with increased systolic hypertension and can alter calcium-channel-blocker and beta-blocker metabolism.[8][11]
• Check adherence and lifestyle measures before diagnosing resistant hypertension or adding fourth-line treatment.[12]Refer patients when secondary or refractory hypertension, target-organ damage or associated conditions cannot be managed in primary care.[4][3]
• Provide each patient with their specific blood-pressure reading and goal at every visit, and reinforce whether control has been achieved.[2][9]

The document does not specify formal programme indicators, routine reporting arrangements, audit requirements, population surveillance, evaluation methods or accountability mechanisms beyond clinical monitoring, follow-up and referral.[1][4][6][10][11]

Costing & Financing

No costing or financing framework is provided. The document does not specify programme costs, budgets, funding sources, allocations, resource-mobilisation measures, funding gaps or economic assumptions.[1][4][5][10][11][9]

• Identify no explicit financial allocation for hypertension prevention, clinical management, monitoring equipment, medicines, referrals, patient education or support groups.[1][9]
• Specify no funding mechanism for implementation by primary health-care services, the National Department of Health or other named stakeholders.[1][5][13]
• Provide no quantified resource requirement, financing gap, affordability assessment, cost-effectiveness analysis or economic assumption.[4][6][8][12][14]